Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Biologic dosing frequency is a significant concern for psoriasis (PsO) patients and physicians.
• Optimizing dosing regimens for biologics remains a clinical challenge.
• Interleukin-17 (IL-17) and Interleukin-23 (IL-23) inhibitors are commonly used for PsO management.

Purpose of the Study:

• To evaluate patient dosing preferences for IL-17 and IL-23 inhibitors.
• To compare patient satisfaction with current dosing frequencies of risankizumab, guselkumab, and ixekizumab.
• To identify factors influencing patient preference for biologic dosing in psoriasis.

Main Methods:

• A phone survey was conducted with 87 adult patients receiving risankizumab (RZB), guselkumab (GUS), or ixekizumab (IXE).
• Patients were assessed for baseline PsO severity, satisfaction with current dosing, flare frequency, and preferred dosing frequency.
• Data were collected from patients treated with biologics from 2019 onward at two clinical sites.

Main Results:

• 87% of patients reported being 'very bothered' by PsO at baseline.
• 86% of patients were satisfied with their current biologic dosing schedule, with no significant differences between RZB, GUS, and IXE.
• A majority of patients preferred maintaining their current dosing frequency (62% RZB, 57% GUS, 48% IXE), with no statistically significant differences across treatment groups.

Conclusions:

• Dosing schedule is not the primary concern for most patients treated with IL-17 and IL-23 inhibitors for psoriasis.
• Effective disease control is the most critical factor for patient satisfaction with psoriasis biologics.
• Tailoring dosing regimens to individual needs may enhance long-term adherence to psoriasis treatments.